The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial

Field	Value	Language
dc.contributor.author	Denholm, Justin T.	en
dc.contributor.author	Davis, Joshua	en
dc.contributor.author	Paterson, David	en
dc.contributor.author	Roberts, Jason	en
dc.contributor.author	Morpeth, Susan	en
dc.contributor.author	Snelling, Thomas	en
dc.contributor.author	Zentner, Dominica	en
dc.contributor.author	Rees, Megan	en
dc.contributor.author	O'Sullivan, Matthew	en
dc.contributor.author	Price, David	en
dc.contributor.author	Bowen, Asha	en
dc.contributor.author	Tong, Steven Y. C.	en
dc.date.accessioned	2020-08-14
dc.date.available	2020-08-14
dc.date.issued	2020	en
dc.identifier.uri	https://hdl.handle.net/2123/23040
dc.description.abstract	Objectives: To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection.	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial	en
dc.type	Article	en
dc.identifier.doi	10.1186/s13063-020-04576-9
dc.relation.other	Health Research Council of New Zealand	en
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en

Associated file/s

There are no files associated with this item.